Using MRI to understand brain tumor biology in patients with glioblastoma
Exploration Into the Association Between Decorin (DCN) Expression and MR Phenotypes in GBM
This study is testing if MRI scans can help doctors understand brain tumors in patients with glioblastoma to see who might benefit from a specific treatment.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Jonsson Comprehensive Cancer Center Academic / other |
| Drugs / interventions | radiation, bevacizumab |
| Locations | 1 site (Los Angeles, California) |
| Trial ID | NCT06090903 on ClinicalTrials.gov |
What this trial studies
This clinical trial utilizes magnetic resonance imaging (MRI) to investigate the biology of brain tumors in patients diagnosed with resectable glioblastoma. The study aims to identify imaging biomarkers that correlate with tumor characteristics and patient outcomes, particularly focusing on the expression of specific proteins and genetic material in tumors with varying diffusion measurements. Patients will undergo one MRI scan prior to surgical resection to gather data that may help predict which individuals will benefit from bevacizumab therapy. The findings could lead to more personalized treatment approaches for glioblastoma patients.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old with newly diagnosed or recurrent glioblastoma that is clinically indicated for surgical resection.
Not a fit: Patients with contraindications to MRI, such as those with pacemakers or metal implants, will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the ability to tailor glioblastoma treatments based on individual tumor biology, potentially improving patient outcomes.
How similar studies have performed: While the approach of using MRI to study tumor biology is established, this specific application in glioblastoma is novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients \> 18 years of age * Patients with newly diagnosed, suspected or recurrent glioblastoma (GBM) patients with enhancing tumors greater than 1.5 mL clinically indicated for surgical resection. Recurrent GBM must have occurred more than 3 months after the end of radiation therapy per Response Assessment in Neuro-Oncology Criteria (RANO) guidelines Exclusion Criteria: * Counterindication to magnetic resonance imaging (MRI) (Patient has a pacemaker or metal in the body) * Patients \< 18 years of age
Where this trial is running
Los Angeles, California
- UCLA / Jonsson Comprehensive Cancer Center — Los Angeles, California, United States (Recruiting)
Study contacts
- Principal investigator: Benjamin M Ellingson — UCLA / Jonsson Comprehensive Cancer Center
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.